Cell Therapies Propel Growth in Anti-Aging Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2026
0mins
Source: PRnewswire
- Market Potential: The global cell therapy market was valued at approximately $4.7 billion in 2023 and is expected to exceed $20 billion by 2030, indicating strong interest from biotech firms and investors in cellular repair and regeneration therapies.
- Anti-Aging Therapy Progress: Avaí Bio and Austrianova have completed the Master Cell Bank (MCB) of α-Klotho protein-overexpressing cells, marking a significant milestone that will advance clinical trial processes aimed at addressing aging-related diseases through cell therapy.
- Focus on Neurodegenerative Diseases: The neurodegenerative disease treatment market is projected to grow from $58.4 billion in 2025 to nearly $85 billion by 2032, reflecting a surge in investment towards disease-modifying therapies, particularly in Alzheimer's and Parkinson's disease.
- New Clinical Trial Developments: BioAge Labs' BGE-102 demonstrated significant reductions in inflammatory biomarkers in its Phase 1 trial, with plans to initiate a Phase 2 cardiovascular risk trial in the first half of 2026 to further validate its therapeutic potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FATE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FATE
Wall Street analysts forecast FATE stock price to rise
9 Analyst Rating
5 Buy
4 Hold
0 Sell
Moderate Buy
Current: 2.930
Low
2.00
Averages
4.64
High
8.00
Current: 2.930
Low
2.00
Averages
4.64
High
8.00
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Stocks Close Higher as Chipmakers Rebound
- Chipmaker Rebound: U.S. stock indices rose as chipmaker stocks rebounded sharply ahead of SK Hynix's Nasdaq debut on July 10, with the S&P 500 up 0.8%, Nasdaq 100 up 1.3%, and Dow Jones Industrial Average up 0.3%, indicating a renewed confidence in tech stocks.
- Strong ETF Performance: Among ETFs tracking benchmark indices, the SPDR S&P 500 ETF (SPY) gained 0.8%, Invesco QQQ Trust (QQQ) rose about 1.6%, and the SPDR Dow Jones Industrial Average ETF Trust (DIA) increased by 0.3%, reflecting sustained investor optimism towards technology stocks.
- Optimistic Market Sentiment: Retail sentiment on Stocktwits for SPY, QQQ, and DIA was between 'extremely bullish' and 'bullish' zones with normal to high message volumes, showcasing investor focus on the upcoming earnings season despite ongoing geopolitical risks.
- Rating Downgrade Impact: S&P Global Ratings downgraded Oracle Corp. to the lowest investment-grade rating, which may negatively impact its stock price, prompting investors to monitor its future performance to assess potential risks.
See More
Fate Therapeutics' FT839 Receives FDA Clearance for Clinical Trial
- Trial Approval: Fate Therapeutics' FT839 has received FDA clearance to initiate early-stage clinical trials in multiple autoimmune diseases, with enrollment expected to begin in the second half of 2026, marking a significant advancement in the company's CAR T therapy portfolio.
- Therapeutic Innovation: FT839 is engineered to eliminate a broader range of disease-driving immune cells compared to existing single-target CAR T therapies, targeting conditions such as rheumatoid arthritis and systemic lupus erythematosus, showcasing its potential in treating complex autoimmune diseases.
- Pipeline Progress: FT839 is the second CAR T candidate from Fate to enter clinical development, following FT819, which is advancing towards a potentially registrational mid-stage study in lupus nephritis later this year, thereby enhancing the company's competitive position in the market.
- Positive Market Reaction: Following the FDA approval, FATE shares surged 6%, having more than tripled year-to-date, reflecting strong investor confidence in the company's future prospects, even as retail sentiment remains neutral.
See More
Fate Therapeutics CAR-T Cell Therapy Receives FDA Clearance
- FDA Approval Milestone: Fate Therapeutics announced that its CAR-T cell therapy FT839 received Investigational New Drug clearance from the U.S. FDA, marking a significant milestone in the biotech sector and paving the way for clinical development.
- Clinical Trial Plans: Following the approval, the company intends to initiate a Phase 1/2 clinical trial in H2 2026 targeting autoimmune diseases, aiming to evaluate the efficacy of FT839 in combination with standard care, highlighting its potential in the treatment landscape.
- Target Disease Scope: The clinical trial will initially focus on autoimmune conditions such as rheumatoid arthritis and ANCA-associated vasculitis, reflecting the company's strategic positioning in diversifying treatment options for complex diseases.
- Subsequent Product Development: FT839 is the second CAR-T cell therapy from Fate Therapeutics to enter clinical studies for autoimmune diseases, following FT819, which is currently in Phase 2 trials for lupus nephritis, demonstrating the company's ongoing commitment and growth potential in the autoimmune treatment space.
See More
Fate Therapeutics Advances Dual-CAR T Cell Therapy into Clinical Development
- FDA IND Approval: Fate Therapeutics has received FDA clearance for its FT839, marking the advancement of its dual-targeting CAR T-cell therapy into clinical trials, with patient enrollment expected to begin in the second half of 2026, aiming to provide new treatment options for autoimmune diseases.
- Multi-Target Design Advantage: FT839 incorporates 13 genetic edits to simultaneously target B cells and CD38-expressing immune cells, which is expected to comprehensively eliminate pathogenic immune cells in various autoimmune disorders, enhancing treatment efficacy while reducing reliance on chemotherapy.
- Innovative Clinical Trial Design: The Phase 1/2 trial utilizes a basket trial design that allows for the assessment of safety and efficacy across multiple autoimmune diseases in a single trial, aiming to accelerate the clinical development process and improve patient access to treatment.
- Strategic Implications: The development of FT839 not only expands Fate Therapeutics' CAR T-cell platform capabilities but also holds potential for new treatment solutions for complex autoimmune diseases and hematologic malignancies, further solidifying the company's leadership position in the biopharmaceutical sector.
See More
Fate Therapeutics Presents Preliminary Clinical Data for FT819 at ISSCR 2026
- Clinical Data Presentation: Fate Therapeutics will present preliminary clinical data for FT819 at the 2026 ISSCR Annual Meeting, focusing on treatment outcomes in systemic sclerosis (SSc) patients, which is expected to garner significant attention and enhance the company's reputation in the biopharmaceutical sector.
- Patient Recruitment Strategy: The study targets treatment-refractory patients with ongoing active disease, broadening entry criteria to include patients with up to 15 years of disease duration, aiming to increase inclusivity and evaluate FT819's efficacy across a wider patient spectrum.
- Efficacy and Safety: Data as of June 12, 2026, indicates that all four SSc patients exhibited significant clinical improvement, with treatment well tolerated and no serious adverse events reported, further validating FT819's potential as a safe and effective CAR T-cell therapy.
- Future Development Plans: FT819 is also being evaluated in systemic lupus erythematosus (SLE), with a Phase 2 potentially registrational trial planned in lupus nephritis, demonstrating the company's ongoing commitment to research and market expansion in autoimmune diseases.
See More
Fate Therapeutics Appoints New Board Member
- New Board Member: Fate Therapeutics has appointed Laura Hamill to its Board of Directors, bringing over 30 years of commercial and strategic management experience in the biopharmaceutical industry, which will be crucial as the company advances its clinical development and prepares for commercialization.
- Transformation Experience: Hamill previously served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences, overseeing approximately $22 billion in annual revenue and successfully transforming the company's commercial organization to restore revenue growth, showcasing her deep expertise in commercialization.
- Advancing Clinical Development: As the company progresses toward later-stage clinical development, Hamill's extensive background will aid Fate Therapeutics in achieving breakthroughs in cell therapy, particularly in treating cancer and autoimmune diseases, thereby enhancing the company's market competitiveness.
- Strategic Development Opportunity: Hamill emphasized that Fate Therapeutics is at a remarkable inflection point, with its innovative cell therapy platform having the potential to change patient treatment, especially in terms of accessibility in community hospitals and underserved regions, indicating significant market opportunities ahead.
See More
U.S. Stocks Close Higher as Chipmakers Rebound
- Chipmaker Rebound: U.S. stock indices rose as chipmaker stocks rebounded sharply ahead of SK Hynix's Nasdaq debut on July 10, with the S&P 500 up 0.8%, Nasdaq 100 up 1.3%, and Dow Jones Industrial Average up 0.3%, indicating a renewed confidence in tech stocks.
- Strong ETF Performance: Among ETFs tracking benchmark indices, the SPDR S&P 500 ETF (SPY) gained 0.8%, Invesco QQQ Trust (QQQ) rose about 1.6%, and the SPDR Dow Jones Industrial Average ETF Trust (DIA) increased by 0.3%, reflecting sustained investor optimism towards technology stocks.
- Optimistic Market Sentiment: Retail sentiment on Stocktwits for SPY, QQQ, and DIA was between 'extremely bullish' and 'bullish' zones with normal to high message volumes, showcasing investor focus on the upcoming earnings season despite ongoing geopolitical risks.
- Rating Downgrade Impact: S&P Global Ratings downgraded Oracle Corp. to the lowest investment-grade rating, which may negatively impact its stock price, prompting investors to monitor its future performance to assess potential risks.
See More
Fate Therapeutics' FT839 Receives FDA Clearance for Clinical Trial
- Trial Approval: Fate Therapeutics' FT839 has received FDA clearance to initiate early-stage clinical trials in multiple autoimmune diseases, with enrollment expected to begin in the second half of 2026, marking a significant advancement in the company's CAR T therapy portfolio.
- Therapeutic Innovation: FT839 is engineered to eliminate a broader range of disease-driving immune cells compared to existing single-target CAR T therapies, targeting conditions such as rheumatoid arthritis and systemic lupus erythematosus, showcasing its potential in treating complex autoimmune diseases.
- Pipeline Progress: FT839 is the second CAR T candidate from Fate to enter clinical development, following FT819, which is advancing towards a potentially registrational mid-stage study in lupus nephritis later this year, thereby enhancing the company's competitive position in the market.
- Positive Market Reaction: Following the FDA approval, FATE shares surged 6%, having more than tripled year-to-date, reflecting strong investor confidence in the company's future prospects, even as retail sentiment remains neutral.
See More
Fate Therapeutics CAR-T Cell Therapy Receives FDA Clearance
- FDA Approval Milestone: Fate Therapeutics announced that its CAR-T cell therapy FT839 received Investigational New Drug clearance from the U.S. FDA, marking a significant milestone in the biotech sector and paving the way for clinical development.
- Clinical Trial Plans: Following the approval, the company intends to initiate a Phase 1/2 clinical trial in H2 2026 targeting autoimmune diseases, aiming to evaluate the efficacy of FT839 in combination with standard care, highlighting its potential in the treatment landscape.
- Target Disease Scope: The clinical trial will initially focus on autoimmune conditions such as rheumatoid arthritis and ANCA-associated vasculitis, reflecting the company's strategic positioning in diversifying treatment options for complex diseases.
- Subsequent Product Development: FT839 is the second CAR-T cell therapy from Fate Therapeutics to enter clinical studies for autoimmune diseases, following FT819, which is currently in Phase 2 trials for lupus nephritis, demonstrating the company's ongoing commitment and growth potential in the autoimmune treatment space.
See More
Fate Therapeutics Advances Dual-CAR T Cell Therapy into Clinical Development
- FDA IND Approval: Fate Therapeutics has received FDA clearance for its FT839, marking the advancement of its dual-targeting CAR T-cell therapy into clinical trials, with patient enrollment expected to begin in the second half of 2026, aiming to provide new treatment options for autoimmune diseases.
- Multi-Target Design Advantage: FT839 incorporates 13 genetic edits to simultaneously target B cells and CD38-expressing immune cells, which is expected to comprehensively eliminate pathogenic immune cells in various autoimmune disorders, enhancing treatment efficacy while reducing reliance on chemotherapy.
- Innovative Clinical Trial Design: The Phase 1/2 trial utilizes a basket trial design that allows for the assessment of safety and efficacy across multiple autoimmune diseases in a single trial, aiming to accelerate the clinical development process and improve patient access to treatment.
- Strategic Implications: The development of FT839 not only expands Fate Therapeutics' CAR T-cell platform capabilities but also holds potential for new treatment solutions for complex autoimmune diseases and hematologic malignancies, further solidifying the company's leadership position in the biopharmaceutical sector.
See More
Fate Therapeutics Presents Preliminary Clinical Data for FT819 at ISSCR 2026
- Clinical Data Presentation: Fate Therapeutics will present preliminary clinical data for FT819 at the 2026 ISSCR Annual Meeting, focusing on treatment outcomes in systemic sclerosis (SSc) patients, which is expected to garner significant attention and enhance the company's reputation in the biopharmaceutical sector.
- Patient Recruitment Strategy: The study targets treatment-refractory patients with ongoing active disease, broadening entry criteria to include patients with up to 15 years of disease duration, aiming to increase inclusivity and evaluate FT819's efficacy across a wider patient spectrum.
- Efficacy and Safety: Data as of June 12, 2026, indicates that all four SSc patients exhibited significant clinical improvement, with treatment well tolerated and no serious adverse events reported, further validating FT819's potential as a safe and effective CAR T-cell therapy.
- Future Development Plans: FT819 is also being evaluated in systemic lupus erythematosus (SLE), with a Phase 2 potentially registrational trial planned in lupus nephritis, demonstrating the company's ongoing commitment to research and market expansion in autoimmune diseases.
See More
Fate Therapeutics Appoints New Board Member
- New Board Member: Fate Therapeutics has appointed Laura Hamill to its Board of Directors, bringing over 30 years of commercial and strategic management experience in the biopharmaceutical industry, which will be crucial as the company advances its clinical development and prepares for commercialization.
- Transformation Experience: Hamill previously served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences, overseeing approximately $22 billion in annual revenue and successfully transforming the company's commercial organization to restore revenue growth, showcasing her deep expertise in commercialization.
- Advancing Clinical Development: As the company progresses toward later-stage clinical development, Hamill's extensive background will aid Fate Therapeutics in achieving breakthroughs in cell therapy, particularly in treating cancer and autoimmune diseases, thereby enhancing the company's market competitiveness.
- Strategic Development Opportunity: Hamill emphasized that Fate Therapeutics is at a remarkable inflection point, with its innovative cell therapy platform having the potential to change patient treatment, especially in terms of accessibility in community hospitals and underserved regions, indicating significant market opportunities ahead.
See More
